Evidence map›Paper›PMID 37223175›Full record

ArticleCureus2023

Eculizumab in the Treatment of Acetylcysteine-Induced Atypical Hemolytic Uremic Syndrome.

Arielle Jalbert, Han Yao, Mylène Fagnan, Benoît Crevier

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Molecules (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Arielle JalbertInternal Medicine Core Program, Université de Sherbrooke (Faculty of Medicine and Health Sciences), Sherbrooke, CAN.
Han YaoNephrology, Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, CAN.
Mylène FagnanPharmacy, Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, CAN.
Benoît CrevierPharmacy, Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, CAN.
Santé Montérégie · CAUniversité de Sherbrooke · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N-acetylcysteine overdose is almost exclusively an iatrogenic event. This rare complication can lead to hemolysis or atypical hemolytic uremic syndrome. A 53-year-old Caucasian male accidentally received a two-fold N-acetylcysteine overdose that resulted in a presentation compatible with the atypical hemolytic uremic syndrome. The patient required temporary hemodialysis sessions, and he received treatment with eculizumab. This case report is the first reported N-acetylcysteine-induced atypical hemolytic uremic syndrome successfully treated with eculizumab. Clinicians should be aware of N-acetylcysteine overdose and its possible hemolytic complications.

Indexed as

acetylcysteineatypical hemolytic uremic syndromeeculizumabhemolysismedication error overdose

Identifiers

PMID37223175
PMCPMC10202342
OpenAlexW4366331504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.